Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation
An. bras. dermatol
;
95(4): 473-476, July-Aug. 2020. graf
Artigo
em Inglês
| LILACS, ColecionaSUS
| ID: biblio-1130913
ABSTRACT
Abstract Vitiligo is a disease that causes macules and achromic and/or hypochromic patches, which can affect from small areas to the entire tegument. Treatment options are few and are generally ineffective. Recently, some case reports have appeared which show positive results with the use of Janus kinase inhibitors associated with phototherapy. This report details the case of a patient with rheumatoid arthritis associated with vitiligo in treatment for two years, whose condition partially improved initially after eight months of oral tofacitinib at a dose of 5 mg twice a day, without exposure to ultraviolet radiation and with continuous improvement during these two years of treatment.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Piperidinas
/
Pirimidinas
/
Pirróis
/
Terapia Ultravioleta
/
Vitiligo
Limite:
Adulto
/
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
An. bras. dermatol
Ano de publicação:
2020
Tipo de documento:
Artigo
Instituição/País de afiliação:
Pontifícia Universidade Católica do Paraná/BR
/
Private Rheumatology Clinic/BR
/
Universidade do Vale do Itajaí/BR
Similares
MEDLINE
...
LILACS
LIS